Page last updated: 2024-10-17

creatine and Idiopathic Parkinson Disease

creatine has been researched along with Idiopathic Parkinson Disease in 79 studies

Research Excerpts

ExcerptRelevanceReference
"To determine whether creatine monohydrate was more effective than placebo in slowing long-term clinical decline in participants with Parkinson disease."9.20Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. ( Aminoff, MJ; Augustine, AH; Augustine, EU; Babcock, D; Bodis-Wollner, IG; Boyd, J; Cambi, F; Chou, K; Christine, CW; Cines, M; Dahodwala, N; Derwent, L; Dewey, RB; Elm, JJ; Hauser, R; Hawthorne, K; Houghton, DJ; Kamp, C; Kieburtz, K; Leehey, M; Lew, MF; Liang, GS; Luo, ST; Mari, Z; Morgan, JC; Parashos, S; Pérez, A; Petrovitch, H; Rajan, S; Reichwein, S; Ross, GW; Roth, JT; Schneider, JS; Shannon, KM; Simon, DK; Simuni, T; Singer, C; Sudarsky, L; Tanner, CM; Tilley, BC; Umeh, CC; Williams, K; Wills, AM, 2015)
"Both creatine and minocycline should be considered for definitive Phase III trials to determine if they alter the long term progression of Parkinson disease (PD)."9.12A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. ( , 2006)
" Weight gain is the most common side effect of Cr, but sporadic reports about the impairment of renal function cause the most concerns with regard to its long-term use."6.73Long-term creatine supplementation is safe in aged patients with Parkinson disease. ( Bender, A; Elstner, M; Klopstock, T; Samtleben, W, 2008)
"Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD."6.72Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. ( Bender, A; Bender, J; Elstner, M; Gasser, T; Gekeler, F; Klopstock, T; Koch, W; Moeschl, M; Müller-Myhsok, B; Schombacher, Y; Tatsch, K, 2006)
"To determine whether creatine monohydrate was more effective than placebo in slowing long-term clinical decline in participants with Parkinson disease."5.20Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. ( Aminoff, MJ; Augustine, AH; Augustine, EU; Babcock, D; Bodis-Wollner, IG; Boyd, J; Cambi, F; Chou, K; Christine, CW; Cines, M; Dahodwala, N; Derwent, L; Dewey, RB; Elm, JJ; Hauser, R; Hawthorne, K; Houghton, DJ; Kamp, C; Kieburtz, K; Leehey, M; Lew, MF; Liang, GS; Luo, ST; Mari, Z; Morgan, JC; Parashos, S; Pérez, A; Petrovitch, H; Rajan, S; Reichwein, S; Ross, GW; Roth, JT; Schneider, JS; Shannon, KM; Simon, DK; Simuni, T; Singer, C; Sudarsky, L; Tanner, CM; Tilley, BC; Umeh, CC; Williams, K; Wills, AM, 2015)
"Both creatine and minocycline should be considered for definitive Phase III trials to determine if they alter the long term progression of Parkinson disease (PD)."5.12A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. ( , 2006)
"We found lower GABA+/creatine in PD with visual hallucinations (0."3.88Reduced occipital GABA in Parkinson disease with visual hallucinations. ( Allan, CL; Blamire, AM; Collerton, D; Firbank, MJ; Killen, A; Murphy, N; Parikh, J; Taylor, JP, 2018)
"This retrospective study aimed to examine the relationship between the ratio of N-acetyl aspartate (NAA) to creatine in the substantia nigra (SN) and globus pallidus (GP) and the Hoehn-Yahr stage and Unified Parkinson Disease Rating Scale (UPDRS) score determined for patients with Parkinson disease (PD)."3.83Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease. ( Chen, J; Huang, MH; Liu, Y; Shen, YJ; Wu, G; Xing, Z, 2016)
"Weight loss is a common symptom of Parkinson's disease and is associated with impaired quality of life."2.84Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort. ( Boyd, J; Li, R; Pérez, A; Ren, X; Wills, AM, 2017)
" Weight gain is the most common side effect of Cr, but sporadic reports about the impairment of renal function cause the most concerns with regard to its long-term use."2.73Long-term creatine supplementation is safe in aged patients with Parkinson disease. ( Bender, A; Elstner, M; Klopstock, T; Samtleben, W, 2008)
"Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD."2.72Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. ( Bender, A; Bender, J; Elstner, M; Gasser, T; Gekeler, F; Klopstock, T; Koch, W; Moeschl, M; Müller-Myhsok, B; Schombacher, Y; Tatsch, K, 2006)
"Twenty-five patients with idiopathic Parkinson disease with unilateral symptoms (IPDUS) and 25 healthy volunteers were enrolled in this study."2.71MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms. ( Liu, Y; Ruan, LX; Shang, DS; Yuan, M; Zhang, LJ; Zheng, XN; Zhu, XC, 2004)
"Creatine has no observed benefit in PD patients, although more correlated studies are still needed."2.55The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials. ( Cui, LL; Liu, LY; Liu, Z; Mo, JJ; Peng, WB; Rao, J, 2017)
"Creatine was selected by the National Institute of Neurological Disorders and Stroke as a possible disease modifying agent for Parkinson's disease."2.55Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease. ( Ahmed, H; Awad, K; El-Jaafary, S; Elnenny, M; Gadelkarim, M; Ghanem, E; Morsi, M; Negida, A, 2017)
"Parkinson's disease is one of the most common neurodegenerative disorders and mitochondrial dysfunction plays an important role in its pathogenesis."2.50Creatine for Parkinson's disease. ( Luo, H; Luo, M; Wang, J; Xiao, Y, 2014)
"Pathological hallmarks of Parkinson's disease are destruction of dopaminergic neurons in the basal ganglia, especially the substantia nigra, and the presence of Lewy bodies within nerve cells."2.46Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. ( Kones, R, 2010)
"Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD."2.42Bioenergetic approaches for neuroprotection in Parkinson's disease. ( Beal, MF, 2003)
"The pathogenesis of Parkinson's disease (PD) remains obscure, but there is increasing evidence that impairment of mitochondrial function, oxidative damage, and inflammation are contributing factors."2.42Mitochondria, oxidative damage, and inflammation in Parkinson's disease. ( Beal, MF, 2003)
"There are several reports of MRS in Parkinson's disease(PD) and multiple system atrophy(MSA)."2.40[Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy]. ( Aotsuka, A; Hattori, T; Shinotoh, H, 1997)
"Curcumin (CUR) has been reported to provide neuroprotective effects on neurological disorders and modulate the gut flora in intestinal-related diseases."1.72Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease. ( Cui, C; Han, Y; Li, G; Li, H; Yu, H; Zhang, B, 2022)
"Diagnosis of Parkinson's disease (PD) cognitive impairment at early stages is challenging compared to the stage of PD dementia where functional impairment is apparent and easily diagnosed."1.62Frontal lobe metabolic alterations characterizing Parkinson's disease cognitive impairment. ( Chaudhary, S; Goyal, V; Jagannathan, NR; Kalaivani, M; Kaloiya, GS; Kumaran, SS; Mehta, N; Sagar, R; Srivastava, AK, 2021)
"Parkinson's disease is characterized by bradykinesia, rigidity, and tremor."1.56GABAergic changes in the thalamocortical circuit in Parkinson's disease. ( Cools, R; den Ouden, HEM; Dirkx, MFM; Helmich, RC; Scheenen, TWJ; Toni, I; van Asten, JJA; van Nuland, AJM; Zach, H, 2020)
"21 patients with Parkinson's disease and 24 controls were examined using magnetic resonance spectroscopic imaging at 3 Tesla."1.40Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. ( Gröger, A; Klose, U; Kolb, R; Schäfer, R, 2014)
"Patients with advanced Parkinson's disease (PD) commonly suffer with significant executive dysfunction and concomitant visual hallucinations."1.38Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. ( Duffy, S; Halliday, G; Lewis, SJ; Naismith, SL; Shine, JM, 2012)
"Nine patients with Parkinson's disease and eight age- and gender-matched healthy controls were included in this study."1.37Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. ( Berg, D; Chadzynski, G; Godau, J; Gröger, A; Klose, U, 2011)
"Although motor symptoms of Parkinson's disease (PD) are initially responsive to dopamine replacement therapy, nonresponsive features develop over time, suggesting that impaired dopaminergic function alone may not be wholly responsible for all the motor features of the disease."1.35Intact presupplementary motor area function in early, untreated Parkinson's disease. ( Camicioli, RM; Gee, M; Hanstock, CC; Martin, WR; Wieler, M, 2008)
"Loss of nigral dopamine neurons in Parkinson's disease induces abnormal activation of glutamate systems in the basal ganglia."1.34Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. ( Durif, F; Fraix, V; Kickler, N; Krack, P; Krainik, A; Lamalle, L; Lebas, JF; Pollak, P; Rémy, C; Segebarth, C, 2007)
"Although no difference was found between groups with RBD and IPD without dream enactment behavior in demographic characteristics, duration of disease, mean levodopa dosage and duration of levodopa use, all UPDRS scores (total, motor and cognitive) were worse in RBD group (p<0."1.33Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior. ( Dincer, A; Hanoglu, L; Meral, H; Ozer, F, 2006)
"The basis for cognitive deficits in Parkinson's disease (PD) is unknown."1.32Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. ( Bastos, AC; Camicioli, RM; Emery, DJ; Fisher, NJ; Foster, SL; Hanstock, CC; Korzan, JR, 2004)
"Six patients with idiopathic Parkinson's disease (IPD), six with clinically probable multiple system atrophy and six control subjects underwent quantitative proton magnetic resonance spectroscopy (MRS)."1.31Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. ( Clarke, CE; Lowry, M, 2000)
"The study included 12 patients with progressive supranuclear palsy, 10 with Parkinson's disease, nine with corticobasal degeneration and 11 age-matched normal control subjects."1.30Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. ( Bertolino, A; Bonavita, S; Hallett, M; Litvan, I; Lundbom, N; Patronas, NJ; Tedeschi, G, 1997)

Research

Studies (79)

TimeframeStudies, this research(%)All Research%
pre-19904 (5.06)18.7374
1990's12 (15.19)18.2507
2000's27 (34.18)29.6817
2010's30 (37.97)24.3611
2020's6 (7.59)2.80

Authors

AuthorsStudies
Donahue, EK1
Bui, V1
Foreman, RP1
Duran, JJ1
Venkadesh, S1
Choupan, J1
Van Horn, JD1
Alger, JR1
Jakowec, MW1
Petzinger, GM1
O'Neill, J1
Cengiz, S1
Arslan, DB1
Kicik, A1
Erdogdu, E1
Yildirim, M1
Hatay, GH1
Tufekcioglu, Z1
Uluğ, AM1
Bilgic, B1
Hanagasi, H1
Demiralp, T1
Gurvit, H1
Ozturk-Isik, E1
Cui, C1
Han, Y1
Li, H1
Yu, H1
Zhang, B1
Li, G1
Yuan, M2
Du, N1
Song, Z1
van Nuland, AJM1
den Ouden, HEM1
Zach, H1
Dirkx, MFM1
van Asten, JJA1
Scheenen, TWJ1
Toni, I1
Cools, R1
Helmich, RC1
Chaudhary, S1
Kumaran, SS1
Goyal, V1
Kalaivani, M1
Kaloiya, GS1
Sagar, R1
Mehta, N1
Srivastava, AK1
Jagannathan, NR1
Simon, DK2
Wu, C1
Tilley, BC5
Lohmann, K1
Klein, C1
Payami, H1
Wills, AM4
Aminoff, MJ3
Bainbridge, J2
Dewey, R1
Hauser, RA2
Schaake, S1
Schneider, JS2
Sharma, S1
Singer, C2
Tanner, CM2
Truong, D1
Wei, P1
Wong, PS1
Yang, T1
Mo, JJ1
Liu, LY1
Peng, WB1
Rao, J1
Liu, Z1
Cui, LL1
Li, R1
Pérez, A3
Ren, X1
Boyd, J2
Barbagallo, G1
Arabia, G1
Morelli, M1
Nisticò, R1
Novellino, F1
Salsone, M1
Rocca, F1
Quattrone, A2
Caracciolo, M1
Sabatini, U1
Cherubini, A1
Firbank, MJ1
Parikh, J1
Murphy, N1
Killen, A1
Allan, CL1
Collerton, D1
Blamire, AM1
Taylor, JP1
Zhou, B1
Yuan, F1
He, Z1
Tan, C1
Gröger, A2
Kolb, R1
Schäfer, R1
Klose, U2
Xiao, Y1
Luo, M1
Luo, H1
Wang, J2
Chagas, MH1
Zuardi, AW1
Tumas, V1
Pena-Pereira, MA1
Sobreira, ET1
Bergamaschi, MM1
dos Santos, AC1
Teixeira, AL1
Hallak, JE1
Crippa, JA1
Ciurleo, R2
Di Lorenzo, G2
Bramanti, P2
Marino, S2
Kieburtz, K1
Elm, JJ5
Babcock, D1
Hauser, R1
Ross, GW2
Augustine, AH1
Augustine, EU1
Bodis-Wollner, IG1
Cambi, F2
Chou, K1
Christine, CW1
Cines, M1
Dahodwala, N1
Derwent, L1
Dewey, RB1
Hawthorne, K1
Houghton, DJ1
Kamp, C1
Leehey, M1
Lew, MF1
Liang, GS2
Luo, ST1
Mari, Z1
Morgan, JC1
Parashos, S1
Petrovitch, H1
Rajan, S1
Reichwein, S1
Roth, JT1
Shannon, KM1
Simuni, T1
Sudarsky, L1
Umeh, CC2
Williams, K1
Li, Z1
Wang, P1
Yu, Z1
Cong, Y1
Sun, H1
Zhang, J2
Sun, C1
Zhang, Y1
Ju, X1
Bonanno, L1
Luo, S2
Augustine, EF2
Dhall, R1
Videnovic, A1
Zweig, RM1
Shulman, LM2
Nance, MA1
Suchowersky, O1
Öz, G1
Seraji-Bozorgzad, N1
Bao, F1
George, E1
Krstevska, S1
Gorden, V1
Chorostecki, J1
Santiago, C1
Zak, I1
Caon, C1
Khan, O1
Almuqbel, M1
Melzer, TR1
Myall, DJ1
MacAskill, MR1
Pitcher, TL1
Livingston, L1
Wood, KL1
Keenan, RJ1
Dalrymple-Alford, JC1
Anderson, TJ1
Wu, G1
Shen, YJ1
Huang, MH1
Xing, Z1
Liu, Y2
Chen, J1
Dorsey, ER1
Kieburtz, KK1
Drew, L1
Ahmed, H1
Gadelkarim, M1
Morsi, M1
Awad, K1
Elnenny, M1
Ghanem, E1
El-Jaafary, S1
Negida, A1
Martin, WR1
Wieler, M1
Gee, M1
Hanstock, CC2
Camicioli, RM2
Griffith, HR1
den Hollander, JA1
Okonkwo, OC1
O'Brien, T1
Watts, RL1
Marson, DC1
Bender, A2
Samtleben, W1
Elstner, M2
Klopstock, T2
Rákóczi, K1
Klivényi, P1
Vécsei, L1
Yang, L1
Calingasan, NY1
Wille, EJ1
Cormier, K1
Smith, K1
Ferrante, RJ1
Beal, MF4
Parashos, SA1
Swearingen, CJ1
Biglan, KM1
Bodis-Wollner, I1
Kones, R1
Williams, R1
Modrego, PJ1
Fayed, N1
Artal, J1
Olmos, S1
Chadzynski, G1
Godau, J1
Berg, D2
Brockmann, K1
Hilker, R1
Pilatus, U1
Baudrexel, S1
Srulijes, K1
Magerkurth, J1
Hauser, AK1
Schulte, C1
Csoti, I1
Merten, CD1
Gasser, T2
Hattingen, E1
Lewis, SJ1
Shine, JM1
Duffy, S1
Halliday, G1
Naismith, SL1
Lawson, AB1
He, B1
Axelson, D1
Bakken, IJ1
Susann Gribbestad, I1
Ehrnholm, B1
Nilsen, G1
Aasly, J1
Rottenberg, DA1
Baik, HM1
Choe, BY2
Son, BC2
Jeun, SS1
Kim, MC2
Lee, KS2
Kim, BS2
Lee, JM1
Lee, HK2
Suh, TS2
Zheng, XN1
Zhu, XC1
Ruan, LX1
Zhang, LJ1
Shang, DS1
Korzan, JR1
Foster, SL1
Fisher, NJ1
Emery, DJ1
Bastos, AC1
Watanabe, H1
Fukatsu, H1
Katsuno, M1
Sugiura, M1
Hamada, K1
Okada, Y1
Hirayama, M1
Ishigaki, T1
Sobue, G1
Brosnan, JT1
Jacobs, RL1
Stead, LM1
Brosnan, ME1
LeWitt, PA1
Hanoglu, L1
Ozer, F1
Meral, H1
Dincer, A1
Koch, W1
Schombacher, Y1
Bender, J1
Moeschl, M1
Gekeler, F1
Müller-Myhsok, B1
Tatsch, K1
Kickler, N1
Krack, P1
Fraix, V1
Lebas, JF1
Lamalle, L1
Durif, F1
Krainik, A1
Rémy, C1
Segebarth, C1
Pollak, P1
Couzin, J1
Bloom, MZ1
Llumiguano, C1
Kovacs, N1
Usprung, Z1
Schwarcz, A1
Dóczi, TP1
Balas, I1
Wilson, TW1
Rajput, AH1
Davie, CA2
Wenning, GK2
Barker, GJ2
Tofts, PS1
Kendall, BE1
Quinn, N2
McDonald, WI1
Marsden, CD1
Miller, DH2
Bowen, BC1
Block, RE1
Sanchez-Ramos, J1
Pattany, PM1
Lampman, DA1
Murdoch, JB1
Quencer, RM1
Brennan, A1
Shiino, A1
Matsuda, M1
Morikawa, S1
Inubushi, T1
Akiguchi, I1
Handa, J1
Aotsuka, A1
Shinotoh, H1
Hattori, T1
Federico, F1
Simone, IL1
Lucivero, V1
De Mari, M1
Giannini, P1
Iliceto, G1
Mezzapesa, DM1
Lamberti, P1
Clarke, CE2
Lowry, M2
Horsman, A1
Ellis, CM1
Lemmens, G1
Williams, SC1
Simmons, A1
Dawson, J1
Leigh, PN1
Chaudhuri, KR1
Cruz, CJ1
Meyerhoff, DJ1
Graham, SH1
Weiner, MW1
Tedeschi, G1
Litvan, I1
Bonavita, S1
Bertolino, A1
Lundbom, N1
Patronas, NJ1
Hallett, M1
Park, JW1
Shinn, KS1
Taylor-Robinson, SD1
Turjanski, N1
Bhattacharya, S1
Seery, JP1
Sargentoni, J1
Brooks, DJ1
Bryant, DJ1
Cox, IJ1
Lucetti, C1
Del Dotto, P1
Gambaccini, G1
Bernardini, S1
Bianchi, MC1
Tosetti, M1
Bonuccelli, U1
Landin, S1
Hagenfeldt, L1
Saltin, B1
Wahren, J1
Dziedzic, SW1
Dziedzic, LB1
Gitlow, SE1
Fine, W1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1)[NCT00449865]Phase 31,741 participants (Actual)Interventional2007-03-31Terminated (stopped due to Futility)
Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease[NCT02324426]Phase 115 participants (Actual)Interventional2014-12-31Completed
Phase 3 Trial of Coenzyme Q10 in Mitochondrial Disease[NCT00432744]Phase 324 participants (Actual)Interventional2007-01-31Completed
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease[NCT00909545]Phase 299 participants (Actual)Interventional2009-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Global Outcome Combined Information on Change From Baseline in Schwab England Activities of Daily Living, 39-Item Parkinson's Disease Questionnaire, Ambulatory Capacity, Symbol Digit Modalities, and Modified Rankin at 5 Years.

All outcomes were coded such that higher scores indicated worse outcomes. Patients were ranked on each outcome and their ranks were summed (summed-ranks). Higher summed ranks (range, 5-4775) indicate worse outcomes. The mean summed ranks were compared by treatment group by a global statistical test (GST). (NCT00449865)
Timeframe: Change from baseline to 5 YEARS

Interventionsummed-ranks (Mean)
Placebo2360
Creatine2414

McMaster Gross Motor Function (GMFM 88)

The McMaster Gross Motor Function is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. One of the links in this report is to the the GMFM scale and how it is scored. A link to the instrument is included. (NCT00432744)
Timeframe: Taken at 6 and 12 Months

Interventionunits on a scale (Median)
Placebo First-0.002
CoenzymeQ10 Frist-0.12

Non-parametric Hotelling T-square Bivariate Analysis of GMGF 88 and OPeds QOL.

This is a multivariate analysis of the first two outcomes: Period 2 minus Period 1 GMFM88 and Peds Quality of Life, analyzed as follows: First, to be in the analysis, subjects must contribute at least one of these endpoints. Second, if the subject became totally disabled during period 1, the difference was defined as + infinity, (highest possible evidence favoring period 2), and if the subject became totally disabled in period 2, the subject was scored as - infinity (highest possible evidence favoring period 1). Period 2 minus period 1 differences were ranked form low to high with missing values scores at the mid-rank. The Hotelling T-square was computed on these ranks and the P-value was obtained from 100,000 rerandomizations as the fraction of rerandomizations with T-sq at least as large as that observed. (NCT00432744)
Timeframe: end of 12 month minus end of 6 month difference.

Interventionparticipants (Number)
Placebo First7
CoenzymeQ10 Frist8

Pediatric Quality of Life Scale

"The Pediatric Quality of Life Scale is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. Goggle pedsQL and Mapi to browse the copyrighted manual. A link to the instrument is included." (NCT00432744)
Timeframe: At 6 and 12 Months

Interventionunits on a scale (Median)
Placebo First-1.1
CoenzymeQ10 Frist-11.9

Common Adverse Events: Back Pain

Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo1
Isradipine CR 5mg/Day0
Isradipine CR 10mg/Day2
Isradipine CR 20mg/Day3

Common Adverse Events: Constipation

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day2
Isradipine CR 10mg/Day3
Isradipine CR 20mg/Day4

Common Adverse Events: Depression

Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day3
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day1

Common Adverse Events: Diarrhoea

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day1
Isradipine CR 10mg/Day2
Isradipine CR 20mg/Day1

Common Adverse Events: Dizziness

Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo7
Isradipine CR 5mg/Day5
Isradipine CR 10mg/Day6
Isradipine CR 20mg/Day6

Common Adverse Events: Dyspepsia

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day1
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day1

Common Adverse Events: Fatigue

General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day1
Isradipine CR 10mg/Day3
Isradipine CR 20mg/Day3

Common Adverse Events: Headache

Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day3
Isradipine CR 10mg/Day6
Isradipine CR 20mg/Day4

Common Adverse Events: Hypotension

Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo1
Isradipine CR 5mg/Day1
Isradipine CR 10mg/Day2
Isradipine CR 20mg/Day2

Common Adverse Events: Insomnia

Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day3
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day1

Common Adverse Events: Nasopharyngitis

Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day4
Isradipine CR 10mg/Day7
Isradipine CR 20mg/Day4

Common Adverse Events: Nausea

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day2
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day2

Common Adverse Events: Oedema Peripheral

General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo1
Isradipine CR 5mg/Day4
Isradipine CR 10mg/Day10
Isradipine CR 20mg/Day16

Common Adverse Events: Sinusitis

Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo3
Isradipine CR 5mg/Day2
Isradipine CR 10mg/Day1
Isradipine CR 20mg/Day0

Common Adverse Events: Somnolence

Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo2
Isradipine CR 5mg/Day3
Isradipine CR 10mg/Day2
Isradipine CR 20mg/Day0

Common Adverse Events: Upper Respiratory Tract Infection

Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo1
Isradipine CR 5mg/Day2
Isradipine CR 10mg/Day5
Isradipine CR 20mg/Day0

Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale

The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo2.60
Isradipine CR 5mg/Day3.20
Isradipine CR 10mg/Day2.09
Isradipine CR 20mg/Day1.86

Efficacy: Change in Beck Depression Inventory II (BDI-II)

The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo-0.52
Isradipine CR 5mg/Day1.99
Isradipine CR 10mg/Day0.11
Isradipine CR 20mg/Day1.50

Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale

The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo0.30
Isradipine CR 5mg/Day0.76
Isradipine CR 10mg/Day0.30
Isradipine CR 20mg/Day0.03

Efficacy: Change in Modified Hoehn & Yahr Scale

The Modified Hoehn & Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn & Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo0.27
Isradipine CR 5mg/Day0.22
Isradipine CR 10mg/Day0.12
Isradipine CR 20mg/Day0.11

Efficacy: Change in Modified Schwab & England Independence Scale

The Schwab & England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab & England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability). (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo-5.04
Isradipine CR 5mg/Day-5.56
Isradipine CR 10mg/Day-3.69
Isradipine CR 20mg/Day-3.76

Efficacy: Change in Montreal Cognitive Assessment

The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo0.58
Isradipine CR 5mg/Day0.06
Isradipine CR 10mg/Day0.11
Isradipine CR 20mg/Day0.36

Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale

The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo4.32
Isradipine CR 5mg/Day3.49
Isradipine CR 10mg/Day3.91
Isradipine CR 20mg/Day3.69

Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39)

The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionunits on a scale (Least Squares Mean)
Placebo1.28
Isradipine CR 5mg/Day3.47
Isradipine CR 10mg/Day3.00
Isradipine CR 20mg/Day3.35

Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS)

Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

InterventionScores on a scale (Least Squares Mean)
Placebo7.40
Isradipine CR 5mg/Day7.44
Isradipine CR 10mg/Day6.30
Isradipine CR 15-20mg/Day5.40

Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR.

Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionparticipants (Number)
Placebo25
Isradipine CR 5mg/Day19
Isradipine CR 10mg/Day19
Isradipine CR 20mg/Day9

Vital Signs: Change in Diastolic Standing

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionmm Hg (Least Squares Mean)
Placebo-0.38
Isradipine CR 5mg/Day-4.20
Isradipine CR 10mg/Day-5.14
Isradipine CR 20mg/Day-4.34

Vital Signs: Change in Diastolic Supine

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionmm Hg (Least Squares Mean)
Placebo0.09
Isradipine CR 5mg/Day-2.79
Isradipine CR 10mg/Day-4.54
Isradipine CR 20mg/Day-3.63

Vital Signs: Change in Pulse Standing

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionbeats per minute (Least Squares Mean)
Placebo-0.08
Isradipine CR 5mg/Day-2.98
Isradipine CR 10mg/Day-2.29
Isradipine CR 20mg/Day-1.21

Vital Signs: Change in Pulse Supine

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionbeats per minute (Least Squares Mean)
Placebo-0.42
Isradipine CR 5mg/Day-0.71
Isradipine CR 10mg/Day-0.52
Isradipine CR 20mg/Day0.18

Vital Signs: Change in Systolic Standing

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionmm Hg (Least Squares Mean)
Placebo-4.77
Isradipine CR 5mg/Day-9.85
Isradipine CR 10mg/Day-7.75
Isradipine CR 20mg/Day-6.30

Vital Signs: Change in Systolic Supine

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Interventionmm Hg (Least Squares Mean)
Placebo-2.45
Isradipine CR 5mg/Day-8.59
Isradipine CR 10mg/Day-6.45
Isradipine CR 20mg/Day-7.01

Reviews

11 reviews available for creatine and Idiopathic Parkinson Disease

ArticleYear
The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials.
    BMC neurology, 2017, Jun-02, Volume: 17, Issue:1

    Topics: Activities of Daily Living; Creatine; Humans; Parkinson Disease; Randomized Controlled Trials as Top

2017
Creatine for Parkinson's disease.
    The Cochrane database of systematic reviews, 2014, Jun-17, Issue:6

    Topics: Activities of Daily Living; Creatine; Humans; Neuroprotective Agents; Parkinson Disease; Quality of

2014
Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?
    BioMed research international, 2014, Volume: 2014

    Topics: Aspartic Acid; Biomarkers; Brain; Choline; Creatine; Humans; Magnetic Resonance Spectroscopy; Molecu

2014
Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease.
    CNS & neurological disorders drug targets, 2017, Volume: 16, Issue:2

    Topics: Animals; Antiparkinson Agents; Creatine; Humans; Neuroprotective Agents; Parkinson Disease; Randomiz

2017
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
    Ideggyogyaszati szemle, 2009, Jan-30, Volume: 62, Issue:1-2

    Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutri

2009
Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition.
    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2010, Volume: 25, Issue:4

    Topics: Anti-Inflammatory Agents; Cholesterol; Creatine; Diet Therapy; Fatty Acids, Omega-3; Humans; Hydroxy

2010
Bioenergetic approaches for neuroprotection in Parkinson's disease.
    Annals of neurology, 2003, Volume: 53 Suppl 3

    Topics: Acetylcarnitine; Coenzymes; Creatine; Energy Metabolism; Free Radicals; Ginkgo biloba; Humans; Mitoc

2003
Mitochondria, oxidative damage, and inflammation in Parkinson's disease.
    Annals of the New York Academy of Sciences, 2003, Volume: 991

    Topics: Animals; Anti-Inflammatory Agents; Coenzymes; Creatine; Disease Models, Animal; Free Radicals; Human

2003
Methylation demand: a key determinant of homocysteine metabolism.
    Acta biochimica Polonica, 2004, Volume: 51, Issue:2

    Topics: Animals; Creatine; Guanidinoacetate N-Methyltransferase; Homocysteine; Humans; Levodopa; Methylation

2004
Clinical trials of neuroprotection for Parkinson's disease.
    Neurology, 2004, Oct-12, Volume: 63, Issue:7 Suppl 2

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Dopamine Agonists; Double-Blind Method; Hu

2004
[Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy].
    Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55, Issue:1

    Topics: Aspartic Acid; Autonomic Nervous System Diseases; Basal Ganglia Diseases; Brain; Choline; Creatine;

1997

Trials

14 trials available for creatine and Idiopathic Parkinson Disease

ArticleYear
Predictors of weight loss in early treated Parkinson's disease from the NET-PD LS-1 cohort.
    Journal of neurology, 2017, Volume: 264, Issue:8

    Topics: Age Factors; Antiparkinson Agents; Creatine; Disease Progression; Dopamine Agents; Double-Blind Meth

2017
Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.
    Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:11

    Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain-Derived Neurotrophic Factor; Cannabidiol; Creatine; Do

2014
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
    JAMA, 2015, Feb-10, Volume: 313, Issue:6

    Topics: Aged; Antiparkinson Agents; Creatine; Disease Progression; Double-Blind Method; Drug Therapy, Combin

2015
The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease.
    European neurology, 2015, Volume: 73, Issue:3-4

    Topics: Aged; Cognition; Cognitive Dysfunction; Creatine; Drug Therapy, Combination; Female; Humans; Male; M

2015
Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Creatine; Double-Blind Method; Female; Humans; Male; Middle Aged; Pa

2015
Long-term creatine supplementation is safe in aged patients with Parkinson disease.
    Nutrition research (New York, N.Y.), 2008, Volume: 28, Issue:3

    Topics: Creatine; Dietary Supplements; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans;

2008
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
    Archives of neurology, 2009, Volume: 66, Issue:9

    Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Creatine; Disability Evaluation; Dise

2009
Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
    Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:12

    Topics: Aged; Antipsychotic Agents; Canada; Creatine; Double-Blind Method; Evidence-Based Medicine; Female;

2012
MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms.
    Journal of Zhejiang University. Science, 2004, Volume: 5, Issue:2

    Topics: Aged; Aspartic Acid; Biomarkers; Choline; Corpus Striatum; Creatine; Humans; Magnetic Resonance Spec

2004
Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker.
    Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:1

    Topics: Aspartic Acid; Brain Stem; Case-Control Studies; Cerebral Cortex; Creatine; Diagnosis, Differential;

2004
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
    Neurology, 2006, Mar-14, Volume: 66, Issue:5

    Topics: Aged; Anti-Bacterial Agents; Creatine; Disabled Persons; Double-Blind Method; Female; Humans; Male;

2006
Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.
    Neurology, 2006, Oct-10, Volume: 67, Issue:7

    Topics: Administration, Oral; Brain; Creatine; Dietary Supplements; Double-Blind Method; Female; Humans; Mal

2006
1H-MRS experiences after bilateral DBS of the STN in Parkinson's disease.
    Parkinsonism & related disorders, 2008, Volume: 14, Issue:3

    Topics: Aged; Aspartic Acid; Choline; Creatine; Deep Brain Stimulation; Female; Humans; Magnetic Resonance S

2008
Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.
    Journal of neurology, neurosurgery, and psychiatry, 1997, Volume: 62, Issue:3

    Topics: Aged; Aspartic Acid; Corpus Striatum; Creatine; Globus Pallidus; Humans; Magnetic Resonance Spectros

1997

Other Studies

54 other studies available for creatine and Idiopathic Parkinson Disease

ArticleYear
Magnetic resonance spectroscopy shows associations between neurometabolite levels and perivascular space volume in Parkinson's disease: a pilot and feasibility study.
    Neuroreport, 2022, 05-04, Volume: 33, Issue:7

    Topics: Aspartic Acid; Brain; Creatine; Feasibility Studies; Humans; Inflammation; Magnetic Resonance Imagin

2022
Identification of metabolic correlates of mild cognitive impairment in Parkinson's disease using magnetic resonance spectroscopic imaging and machine learning.
    Magma (New York, N.Y.), 2022, Volume: 35, Issue:6

    Topics: Cognitive Dysfunction; Creatine; Humans; Inositol; Machine Learning; Magnetic Resonance Imaging; Mag

2022
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Frontiers in cellular and infection microbiology, 2022, Volume: 12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Curcumin; Disease Models, Animal; G

2022
Primary motor area-related injury of anterior central gyrus in Parkinson's disease with dyskinesia: A study based on MRS and Q-space.
    Neuroscience letters, 2023, 05-14, Volume: 805

    Topics: Aspartic Acid; Brain; Choline; Creatine; Dyskinesias; Humans; Magnetic Resonance Imaging; Magnetic R

2023
GABAergic changes in the thalamocortical circuit in Parkinson's disease.
    Human brain mapping, 2020, Volume: 41, Issue:4

    Topics: Aged; Creatine; Dopamine Agents; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectro

2020
Frontal lobe metabolic alterations characterizing Parkinson's disease cognitive impairment.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:3

    Topics: Aspartic Acid; Brain; Cognitive Dysfunction; Creatine; Frontal Lobe; Gray Matter; Humans; Magnetic R

2021
Caffeine, creatine, GRIN2A and Parkinson's disease progression.
    Journal of the neurological sciences, 2017, Apr-15, Volume: 375

    Topics: Aged; Caffeine; Creatine; Disease Progression; Female; Gene-Environment Interaction; Genetic Predisp

2017
Thalamic neurometabolic alterations in tremulous Parkinson's disease: A preliminary proton MR spectroscopy study.
    Parkinsonism & related disorders, 2017, Volume: 43

    Topics: Aged; Aspartic Acid; Choline; Creatine; Discriminant Analysis; Dopamine Plasma Membrane Transport Pr

2017
Reduced occipital GABA in Parkinson disease with visual hallucinations.
    Neurology, 2018, 08-14, Volume: 91, Issue:7

    Topics: Aged; Aged, 80 and over; Cognition Disorders; Creatine; Female; gamma-Aminobutyric Acid; Gray Matter

2018
Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease.
    Brain imaging and behavior, 2014, Volume: 8, Issue:1

    Topics: Adult; Aged; Choline; Creatine; Dipeptides; Female; Humans; Magnetic Resonance Spectroscopy; Male; M

2014
Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Creatine; Dopamine; Humans; Magnetic Resonance I

2014
Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
    Neuroscience letters, 2015, Jul-10, Volume: 599

    Topics: Antiparkinson Agents; Aspartic Acid; Case-Control Studies; Choline; Creatine; Dopamine Agonists; Fem

2015
Bayesian multivariate augmented Beta rectangular regression models for patient-reported outcomes and survival data.
    Statistical methods in medical research, 2017, Volume: 26, Issue:4

    Topics: Bayes Theorem; Creatine; Humans; Longitudinal Studies; Markov Chains; Models, Statistical; Monte Car

2017
MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:10

    Topics: Aspartic Acid; Creatine; Female; Humans; Male; Parkinson Disease; Proton Magnetic Resonance Spectros

2015
Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:10

    Topics: Aged; Aspartic Acid; Biomarkers; Creatine; Female; Humans; Longitudinal Studies; Male; Middle Aged;

2015
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
    Parkinsonism & related disorders, 2016, Volume: 22

    Topics: Aged; Aged, 80 and over; Aspartic Acid; Bayes Theorem; Case-Control Studies; Choline; Cognitive Dysf

2016
Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease.
    AJR. American journal of roentgenology, 2016, Volume: 206, Issue:2

    Topics: Aged; Aspartic Acid; Creatine; Female; Globus Pallidus; Humans; Magnetic Resonance Spectroscopy; Mal

2016
Communicating with participants during the conduct of multi-center clinical trials.
    Clinical trials (London, England), 2016, Volume: 13, Issue:6

    Topics: Canada; Clinical Trials as Topic; Communication; Creatine; Double-Blind Method; Humans; Information

2016
Two hundred steps.
    Nature, 2016, 10-27, Volume: 538, Issue:7626

    Topics: alpha-Synuclein; Creatine; Deep Brain Stimulation; Disease Progression; Dopamine; Fetal Tissue Trans

2016
Intact presupplementary motor area function in early, untreated Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Sep-15, Volume: 23, Issue:12

    Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Creatine; Female; Humans; Magnetic Resonance Spe

2008
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.
    Alzheimer's & dementia : the journal of the Alzheimer's Association, 2008, Volume: 4, Issue:6

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Case-Control Studie

2008
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
    Journal of neurochemistry, 2009, Volume: 109, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis

2009
Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease.
    Parkinsonism & related disorders, 2009, Volume: 15 Suppl 3

    Topics: Animals; Clinical Trials, Phase III as Topic; Creatine; Heat-Shock Proteins; Histocompatibility Anti

2009
Slowing the decline.
    Nature, 2010, Aug-26, Volume: 466, Issue:7310

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Humans; Indans; Parkinson Disease; Selegil

2010
Correlation of findings in advanced MRI techniques with global severity scales in patients with Parkinson disease.
    Academic radiology, 2011, Volume: 18, Issue:2

    Topics: Aged; Brain; Choline; Corpus Striatum; Creatine; Diffusion Tensor Imaging; Dipeptides; Female; Gluta

2011
Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease.
    European radiology, 2011, Volume: 21, Issue:9

    Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Creatine; Female; Humans; Imaging, Three-Dimensi

2011
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure.
    Neurology, 2012, Jul-17, Volume: 79, Issue:3

    Topics: Adenosine Diphosphate; Adult; Age of Onset; Aged; Algorithms; Aspartic Acid; Brain Chemistry; Cholin

2012
Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2012, Sep-01, Volume: 27, Issue:10

    Topics: Aged; Aspartic Acid; Case-Control Studies; Cognition Disorders; Creatine; Female; Gyrus Cinguli; Hum

2012
Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial.
    Statistical methods in medical research, 2016, Volume: 25, Issue:2

    Topics: Bayes Theorem; Creatine; Humans; Longitudinal Studies; Parkinson Disease

2016
Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients.
    Journal of magnetic resonance imaging : JMRI, 2002, Volume: 16, Issue:1

    Topics: Aged; Aspartic Acid; Basal Ganglia; Case-Control Studies; Choline; Creatine; Female; Humans; Magneti

2002
Why Rome trembles: "E avanti a lui tremava tutta Roma!" (Tosca, Act II).
    Neurology, 2003, Apr-22, Volume: 60, Issue:8

    Topics: Aspartic Acid; Cerebellum; Choline; Creatine; Essential Tremor; Humans; Magnetic Resonance Spectrosc

2003
Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy.
    European journal of radiology, 2003, Volume: 47, Issue:3

    Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Female; Humans; Magnetic Resonance Spectroscopy; Mal

2003
Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia.
    Neuroscience letters, 2004, Jan-16, Volume: 354, Issue:3

    Topics: Aged; Aspartic Acid; Case-Control Studies; Choline; Cognition; Creatine; Female; Gyrus Cinguli; Huma

2004
Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior.
    Clinical neurology and neurosurgery, 2006, Volume: 108, Issue:2

    Topics: Aged; Aspartic Acid; Brain Stem; Case-Control Studies; Choline; Creatine; Female; Humans; Inositol;

2006
Certain drugs might slow progression of Parkinson's disease.
    Health news (Waltham, Mass.), 2006, Volume: 12, Issue:5

    Topics: Brain; Creatine; Dopamine; Humans; Minocycline; Parkinson Disease

2006
Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
    NMR in biomedicine, 2007, Volume: 20, Issue:8

    Topics: Antiparkinson Agents; Aspartic Acid; Corpus Striatum; Creatine; gamma-Aminobutyric Acid; Glutamic Ac

2007
Clinical research. Testing a novel strategy against Parkinson's disease.
    Science (New York, N.Y.), 2007, Mar-30, Volume: 315, Issue:5820

    Topics: Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Creatine; Dietary Supplements; Humans;

2007
NIH announces phase III clinical trial of creatine for Parkinson's disease.
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2007, Volume: 22, Issue:5

    Topics: Clinical Trials, Phase III as Topic; Creatine; Dietary Supplements; Humans; National Institutes of H

2007
Amantadine-dyazide interaction.
    Canadian Medical Association journal, 1983, Nov-01, Volume: 129, Issue:9

    Topics: Amantadine; Ataxia; Creatine; Diuresis; Drug Combinations; Drug Synergism; Edema; Humans; Hydrochlor

1983
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy.
    Annals of neurology, 1995, Volume: 37, Issue:2

    Topics: Adult; Aged; Aspartic Acid; Atrophy; Basal Ganglia; Brain Diseases; Choline; Creatine; Diagnosis, Di

1995
Proton MR spectroscopy of the brain in 14 patients with Parkinson disease.
    AJNR. American journal of neuroradiology, 1995, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Creatine; Dementia; Energy Metabolism

1995
MRS to differentiate multiple system atrophy from idiopathic Parkinson's disease.
    Lancet (London, England), 1993, Sep-11, Volume: 342, Issue:8872

    Topics: Adult; Aged; Aspartic Acid; Basal Ganglia; Central Nervous System Diseases; Creatine; Humans; Magnet

1993
Proton magnetic resonance spectroscopy with dementia.
    Surgical neurology, 1993, Volume: 39, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatine; Dementia; Female; Humans

1993
Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.
    Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:3

    Topics: Aged; Apomorphine; Aspartic Acid; Basal Ganglia; Choline; Creatine; Glutamic Acid; Humans; Magnetic

1997
Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study.
    Neurology, 1997, Volume: 49, Issue:2

    Topics: Adult; Aged; Antiparkinson Agents; Aspartic Acid; Choline; Creatine; Dopamine Agents; Humans; Levodo

1997
Proton MR spectroscopic imaging of the striatum in Parkinson's disease.
    Magnetic resonance imaging, 1997, Volume: 15, Issue:6

    Topics: Adult; Aged; Aspartic Acid; Biomarkers; Choline; Corpus Striatum; Creatine; Female; Humans; Magnetic

1997
Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
    Brain : a journal of neurology, 1997, Volume: 120 ( Pt 9)

    Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Brain Diseases; Choline; Creatine; Female; Humans; Ma

1997
Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy.
    Investigative radiology, 1998, Volume: 33, Issue:8

    Topics: Adult; Aged; Aspartic Acid; Brain Chemistry; Choline; Creatine; Female; Globus Pallidus; Humans; Mag

1998
A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.
    Metabolic brain disease, 1999, Volume: 14, Issue:1

    Topics: Aged; Aspartic Acid; Cerebral Cortex; Choline; Corpus Striatum; Creatine; Female; Glutamic Acid; Glu

1999
Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy.
    European journal of neurology, 2000, Volume: 7, Issue:6

    Topics: Adult; Aged; Aspartic Acid; Basal Ganglia; Choline; Creatine; Glutamic Acid; Glutamine; Humans; Magn

2000
Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2001, Volume: 22, Issue:1

    Topics: Aged; Aspartic Acid; Basal Ganglia; Brain Chemistry; Choline; Creatine; Female; Humans; Inositol; Ma

2001
Muscle metabolism during exercise in patients with Parkinson's disease.
    Clinical science and molecular medicine, 1974, Volume: 47, Issue:5

    Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Aged; Blood Flow Velocity; Blood Glucose; Carbon

1974
Separation and determination of urinary homovanillic acid and iso-homovanillic acid by gas-liquid chromatography and electron capture detection.
    The Journal of laboratory and clinical medicine, 1973, Volume: 82, Issue:5

    Topics: Adolescent; Adult; Child; Chromatography, Gas; Creatine; Dihydroxyphenylalanine; Homovanillic Acid;

1973
Some common factors in the causation of postural hypotension.
    Gerontologia clinica, 1969, Volume: 11, Issue:4

    Topics: 17-Ketosteroids; Aged; Arrhythmias, Cardiac; Asthenia; Blood Pressure; Blood Volume; Chlorides; Crea

1969